Dyadic to Report 2024 Full Year Financial Results and Host Conference call on Wednesday, March 26, 2025
Dyadic International (Nasdaq: DYAI), a biotechnology company specializing in large-scale protein manufacturing for human and animal vaccines, therapeutics, and non-pharmaceutical applications, has announced its upcoming 2024 full-year financial results release and conference call.
The company will host the corporate update conference call on Wednesday, March 26, 2025, at 5:00 p.m. Eastern Time. Investors can access the call through toll-free (+1-877-407-0784) or international (+1-201-689-8560) numbers using Conference ID 13751386. A webcast will also be available, with an archive accessible within 24 hours on Dyadic's Investor Relations website.
Dyadic International (Nasdaq: DYAI), un'azienda biotech specializzata nella produzione su larga scala di proteine per vaccini, terapie e applicazioni non farmaceutiche per esseri umani e animali, ha annunciato il rilascio dei risultati finanziari per l'intero anno 2024 e la relativa conference call.
L'azienda ospiterà la conference call di aggiornamento aziendale mercoledì 26 marzo 2025, alle 17:00 ora orientale. Gli investitori possono accedere alla call tramite numeri gratuiti (+1-877-407-0784) o internazionali (+1-201-689-8560) utilizzando l'ID conferenza 13751386. Sarà disponibile anche un webcast, con un archivio accessibile entro 24 ore sul sito delle Relazioni con gli Investitori di Dyadic.
Dyadic International (Nasdaq: DYAI), una empresa biotecnológica especializada en la fabricación a gran escala de proteínas para vacunas, terapias y aplicaciones no farmacéuticas para humanos y animales, ha anunciado la próxima publicación de sus resultados financieros del año completo 2024 y la conferencia telefónica correspondiente.
La empresa llevará a cabo la conferencia telefónica de actualización corporativa el miércoles 26 de marzo de 2025, a las 5:00 p.m. hora del Este. Los inversores pueden acceder a la llamada a través de números gratuitos (+1-877-407-0784) o internacionales (+1-201-689-8560) utilizando el ID de conferencia 13751386. También estará disponible una transmisión en vivo, con un archivo accesible dentro de las 24 horas en el sitio web de Relaciones con Inversores de Dyadic.
다이아딕 인터내셔널 (Nasdaq: DYAI)은 인간 및 동물 백신, 치료제 및 비의료 응용 프로그램을 위한 대규모 단백질 제조를 전문으로 하는 생명공학 회사로, 2024 회계연도 전체 재무 결과 발표 및 컨퍼런스 콜을 곧 개최한다고 발표했습니다.
회사는 2025년 3월 26일 수요일, 동부 표준시 오후 5:00에 기업 업데이트 컨퍼런스 콜을 진행합니다. 투자자들은 무료 전화 (+1-877-407-0784) 또는 국제 전화 (+1-201-689-8560)를 통해 회의 ID 13751386을 사용하여 전화를 연결할 수 있습니다. 또한, Dyadic의 투자자 관계 웹사이트에서 24시간 이내에 접근 가능한 아카이브가 있는 웹캐스트도 제공됩니다.
Dyadic International (Nasdaq: DYAI), une entreprise de biotechnologie spécialisée dans la fabrication de protéines à grande échelle pour les vaccins, les thérapies et les applications non pharmaceutiques pour les humains et les animaux, a annoncé la prochaine publication de ses résultats financiers pour l'année 2024 et la conférence téléphonique qui l'accompagne.
L'entreprise organisera la conférence téléphonique de mise à jour d'entreprise le mercredi 26 mars 2025, à 17h00, heure de l'Est. Les investisseurs peuvent accéder à l'appel via des numéros gratuits (+1-877-407-0784) ou internationaux (+1-201-689-8560) en utilisant l'ID de conférence 13751386. Un webinaire sera également disponible, avec un enregistrement accessible dans les 24 heures sur le site des relations avec les investisseurs de Dyadic.
Dyadic International (Nasdaq: DYAI), ein Biotechnologieunternehmen, das sich auf die großtechnische Herstellung von Proteinen für menschliche und tierische Impfstoffe, Therapeutika und nicht-pharmazeutische Anwendungen spezialisiert hat, hat die bevorstehende Veröffentlichung der Jahresfinanzzahlen 2024 und die dazugehörige Telefonkonferenz angekündigt.
Das Unternehmen wird die Unternehmensupdate-Telefonkonferenz am Mittwoch, den 26. März 2025, um 17:00 Uhr Eastern Time ausrichten. Investoren können über die gebührenfreie Nummer (+1-877-407-0784) oder internationale Nummer (+1-201-689-8560) unter Verwendung der Konferenz-ID 13751386 auf die Konferenz zugreifen. Ein Webcast wird ebenfalls verfügbar sein, mit einem Archiv, das innerhalb von 24 Stunden auf der Investor-Relations-Website von Dyadic zugänglich ist.
- None.
- None.
JUPITER, Fla., March 12, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications, today announced that it will report its financial results for the year ended 2024 and host a corporate update conference call on Wednesday, March 26, 2025.
Conference Call Information
Date: Wednesday, March 26, 2025
Time: 5:00 p.m. Eastern Time
Dial-in numbers: Toll Free: +1-877-407-0784; International +1-201-689-8560
Conference ID: 13751386
Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1705988&tp_key=509eb4b293. An archive of the webcast will be available within 24 hours after completion of the live event and will be accessible on the Investor Relations section of the Company's website at www.dyadic.com. To access the replay of the webcast, please follow the webcast link above.
If you have any questions that you would like to ask management during the Q&A session, please email jlavalley@dyadic.com prior to the conference call.
About Dyadic International, Inc.
Dyadic International, Inc., is a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness.
Dyadic’s microbial gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Our lead platform, the C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is currently used to speed development, lower production costs, and potentially improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. Dyadic has also developed the DapibusTM protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, such as food, nutrition, and wellness.
Dyadic is focusing on leveraging its microbial platform technologies for itself and its collaborators in a wide range of applications, including human and animal vaccines, therapeutics, food, nutrition, wellness, and internal biological products.
For more information about Dyadic International, visit www.dyadic.com.
Safe Harbor Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic International’s expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of our clinical trial and interest in our protein production platforms, our research projects and third-party collaborations, as well as the availability of necessary funding. Actual events or results may differ materially from those in the forward-looking statements because of various important factors, including those described in the Company’s most recent filings with the SEC. Dyadic assumes no obligation to update publicly any such forward-looking statements, whether because of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled “Risk Factors” in Dyadic’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic’s periodic filings with the SEC, which are accessible on the SEC’s website and at www.dyadic.com.
Contact:
Dyadic International, Inc.
Ping W. Rawson
Chief Financial Officer
Phone: (561) 743-8333
Email: ir@dyadic.com
FAQ
When will Dyadic (DYAI) release its 2024 full-year financial results?
How can investors join Dyadic's (DYAI) 2024 earnings conference call?
What time is Dyadic's (DYAI) 2024 earnings call scheduled for?
Where can investors access the replay of Dyadic's (DYAI) 2024 earnings call?
